The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.
about
Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseasesOpening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular riskEarly Cellular Changes in the Ascending Aorta and Myocardium in a Swine Model of Metabolic SyndromeApolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosisCeramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosisSerum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography.Characterization of the metabolic profile associated with serum 25-hydroxyvitamin D: a cross-sectional analysis in population-based data.Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell diseaseApolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee.Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profileHigh density lipoproteins and type 2 diabetes: Emerging concepts in their relationship.Cardiovascular risk according to plasma apolipoprotein and lipid profiles in a Canadian First Nation.Effects of NS Lactobacillus strains on lipid metabolism of rats fed a high-cholesterol dietThe apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity.Argan Oil Exerts an Antiatherogenic Effect by Improving Lipids and Susceptibility of LDL to Oxidation in Type 2 Diabetes Patients.A 2-Week Course of Enteral Treatment with a Very Low-Calorie Protein-Based Formula for the Management of Severe Obesity.Interaction of age with lipoproteins as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis.Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial.Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients.A Novel Anti-Inflammatory Effect for High Density Lipoprotein.Reduced cardiovascular risk after bariatric surgery is linked to plasma ceramides, apolipoprotein-B100, and ApoB100/A1 ratio.Is the ratio of apoB/apoA-1 the best predictor for the severity of coronary artery lesions in Chinese diabetics with stable angina pectoris? An assessment based on Gensini scores.Hierarchical modelling of blood lipids' profile and 10-year (2002-2012) all cause mortality and incidence of cardiovascular disease: the ATTICA study.Relationship between PON1L55M and Q192R gene polymorphisms and high APO B/APO A-I ratiosThe apoB100/apoAI ratio is independently associated with the severity of coronary heart disease: a cross sectional study in patients undergoing coronary angiography.Serum apolipoproteins in relation to intakes of fish in population of Arkhangelsk CountyApo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies.The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.Lipoprotein metabolism in nonalcoholic fatty liver diseaseBiochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools.Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis.Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population.Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use.Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention.Evaluation of Lipid Profile and Apolipoproteins in Essential Hypertensive Patients.Changes in serum inflammatory markers are associated with changes in apolipoprotein A1 but not B after the initiation of dialysisLifestyle and Dietary Determinants of Serum Apolipoprotein A1 and Apolipoprotein B Concentrations: Cross-Sectional Analyses within a Swedish Cohort of 24,984 Individuals.Obesity contributes more to increasing ApoB/ApoA1 ratio than hyperandrogenism in PCOS women aged 20-38 years in China.The relationship between high density lipoprotein subclass profile and apolipoprotein concentrations.
P2860
Q21285153-571DA4C0-A31E-419C-8163-38E04E2F60AAQ24626884-90A68472-571A-40D5-8CCC-2EE0E1D5714EQ27332290-05422753-8E54-4037-8746-596363361523Q28278173-79479642-8E32-41EE-992E-25535B901B7AQ28547365-B29B79E8-702C-4DA6-BE34-FF31266428F6Q31108335-9813EF05-A3C9-40FF-B7F2-DC771175DC72Q31127455-94CA6E90-C802-441D-8D60-F84A99076763Q33385956-3E6B5F4F-DDD8-4CE4-8E10-B37B365B060CQ33572201-B0BBA30C-852D-40CF-A433-10C3E3135D2AQ33785827-2A89C3F8-1E61-4A44-A490-745493380D37Q33814212-AE4833C5-4C2A-48F8-8AE9-6A63EF3BDA8CQ34600040-1B39E8F1-615C-47A5-AD72-5F24EDA04EEEQ34711117-31C83601-8113-4BF6-949B-400DE257DFCDQ35234169-058AA93C-D42F-4C91-8E6D-275573436BC9Q35505555-2FE45E22-0BA4-418F-8F1C-B75669D29697Q35625824-DC920849-CD24-4B66-80C4-EC1B13482B75Q35635352-B1B25AFF-73D8-4C1E-A57A-FD8169707181Q35667598-39E70B14-FF64-496E-96D6-4F9C46238F46Q35807156-2F3BBA8E-04CD-4827-98B3-BFC12D903165Q35872393-2B98AD29-EEE3-4BF9-8ED2-3B3614B7364BQ35916568-6A5BA5CA-4ED3-4617-802D-2056A5589081Q36011273-DC348F1E-8BD9-4D81-9AAF-1FC3AF80C9DFQ36061533-20A1B771-7312-4AD2-B9C9-4530C16B28CFQ36262987-FD3DCB7E-FBED-4F12-A16A-973B6D500029Q36298497-1A166A4E-C878-4A88-B0E2-653874EC07CEQ36392380-7837F495-9470-41C5-9A25-32D936C0FFB1Q36395720-FC36F098-57CB-4F70-B814-558C0B70D703Q36455898-79AC7F94-617E-40A2-A356-DC1B4B735E38Q36455901-382F5A83-5565-4E4F-93CE-A73B82B44C95Q36682138-83E1271A-638B-4495-8B1B-E3F8C8DB369CQ36738090-718BA287-843B-4DF3-A992-3CDBA7201197Q37277947-754C8FB7-EC06-4663-A4C2-C40E1FABDE14Q37291503-530BFC0D-1AA2-4902-BDF7-679B7E53D956Q37327222-96BA890B-C227-4085-85E9-87102449B413Q37354657-89FEE68C-14FB-4972-BE27-5D8F693FEED1Q37435355-1BAFFCB9-A429-456F-9B7F-7C2D876954A5Q37542828-FBE8C7F8-2F4A-4EE9-BA3F-D1D63FCF28E9Q37729655-9F53FF15-1B8A-4C5A-B4B8-7A2BB7A04443Q37734592-18B80E4D-BD49-4A77-BCAA-E5731760033AQ37900093-C2B20C86-8130-4BFF-9B3C-461C8709B38D
P2860
The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
The apoB/apoA-I ratio is bette ...... and to predict coronary risk.
@en
The apoB/apoA-I ratio is bette ...... and to predict coronary risk.
@nl
type
label
The apoB/apoA-I ratio is bette ...... and to predict coronary risk.
@en
The apoB/apoA-I ratio is bette ...... and to predict coronary risk.
@nl
prefLabel
The apoB/apoA-I ratio is bette ...... and to predict coronary risk.
@en
The apoB/apoA-I ratio is bette ...... and to predict coronary risk.
@nl
P2093
P2860
P356
P1476
The apoB/apoA-I ratio is bette ...... and to predict coronary risk.
@en
P2093
Allan D Sniderman
Are H Aastveit
Curt D Furberg
Göran Walldius
Ingar Holme
Ingmar Jungner
P2860
P304
P356
10.1515/CCLM.2004.254
P577
2004-01-01T00:00:00Z